Experimental Compound Targets C. difficile While Preserving Gut Microbes
Researchers found that argyrin B, a natural compound produced by soil myxobacteria, selectively kills Clostridioides difficile while leaving much of the gut microbiome intact. In laboratory tests and a mouse infection model, oral treatment lowered bacterial levels and remained mainly in the large intestine, with little reaching the bloodstream. The approach is being explored as a possible alternative to stool transplants for recurrent C. difficile infections.
C. difficile often resides in human intestines without causing illness when scarce. If it overgrows, toxins can inflame the gut acutely, sometimes chronically and dangerously. These infections are a major source of antibiotic-linked diarrhea and frequently return, prompting stool transplants in recurrent cases.
Argyrin B comes from soil myxobacteria, organisms that use natural compounds against other microbes. In mouse studies, oral dosing concentrated the candidate in the large intestine and kept most out of the bloodstream. It acts on an antibacterial target previously characterized in Pseudomonas aeruginosa and appears to spare beneficial digestive-tract microbes.
If argyrin B advances, patients with recurrent C. difficile infections could gain an oral option that may be easier than stool transplants. Because it appears to stay in the large intestine, it might limit systemic side effects and preserve more of the gut microbiome, potentially reducing relapse risk. Hospitals and clinicians may also benefit from a targeted treatment that could simplify care, though human safety and efficacy remain unproven.